Amneal Pharmaceuticals Quarterly Cash Flow Statement
NASDAQ: AMRXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Amneal Pharmaceuticals free cash flow
In the quarter ended Jun 30, 2026, Amneal Pharmaceuticals generated -$21.2 million of operating cash flow and spent $30.7 million on capital expenditures. That left free cash flow of -$51.9 million, a free-cash-flow margin of -6.5% of revenue. Free cash flow was down 185.2% from the prior year's $61.0 million.
Summary generated from market data by MetaCap's automated system. Methodology
Amneal Pharmaceuticals cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 69.61M | 78.00M | 49.57M | 18.13M | 35.61M | 24.62M | -20.74M | 11.76M | 16.79M | -81.68M | -93.34M | 25.03M |
| Net Income growth (YoY) | +95.49% | +216.84% | — | +54.22% | +112.13% | — | — | -53.03% | -43.45% | — | — | — |
| Stock-Based Compensation | 10.39M | 8.82M | 8.20M | 8.22M | 8.27M | 7.26M | 7.21M | 7.11M | 6.72M | 6.72M | 5.97M | 6.69M |
| Change in Working Capital | -183.06M | -148.92M | -10.93M | -48.83M | -40.42M | -105.25M | -13.21M | 31.90M | -60.77M | -16.91M | 47.39M | -34.50M |
| Operating Cash Flow | -21.24M | -26.74M | 130.31M | 118.45M | 83.82M | 7.41M | 118.08M | 141.77M | 39.66M | -4.41M | 135.82M | 81.39M |
| Capital Expenditures | -30.70M | -8.18M | -21.77M | -12.30M | -22.83M | -13.16M | -15.15M | -16.95M | -10.63M | -9.20M | -9.87M | -11.66M |
| Investing Cash Flow | -122.74M | -21.71M | -45.45M | -22.46M | -26.55M | -17.80M | -16.06M | -20.71M | -6.46M | -19.76M | -31.69M | -13.48M |
| Debt Issued | 0 | 134.67M | — | — | 0 | 0 | — | — | — | — | — | — |
| Financing Cash Flow | 79.36M | -59.05M | -10.12M | 59.44M | -41.69M | -39.17M | -61.20M | -92.35M | -35.09M | -23.16M | -100.83M | -86.58M |
| Net Change in Cash | -64.79M | -108.53M | 74.53M | 154.74M | 15.28M | -50.03M | 40.08M | 28.72M | -2.00M | -47.49M | 3.50M | -18.98M |
| Free Cash Flow | -51.94M | -34.92M | 108.54M | 106.15M | 60.99M | -5.75M | 102.92M | 124.83M | 29.03M | -13.61M | 125.96M | 69.73M |
This table shows 12 quarterly periods of Amneal Pharmaceuticals's cash flow statement, from Q2 2026 back to Q3 2023, across 12 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow AMRX's reporting calendar. What is a cash flow statement?